---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-007580"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:36:42.763896+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports FY 2022 net loss of $29.0M; cash $43.1M, runway into Q3 2024

## Summary
- Net loss $29.0M for 2022 vs $6.7M in 2021; R&D expense $19.0M (up $4.6M), G&A $11.5M.
- Cash and equivalents $43.1M as of Dec 31, 2022; sufficient to fund ops into Q3 2024.
- Annamycin Phase 1/2 trial in AML approved in Italy; first subjects dosed.
- FDA granted Fast Track Designation for WP1122 in Glioblastoma Multiforme.
- European Phase 1 Annamycin trial reported 80% overall response rate in final cohort.

## SEC filing metadata
- accession: 0001437749-23-007580
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774923007580/0001437749-23-007580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774923007580/mbrx20230321_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-007580
- JSON: https://secwatch.observer/filing/0001437749-23-007580.json
- Plain text: https://secwatch.observer/filing/0001437749-23-007580.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2022 results: net income $29.0 million.
  - Period: the fiscal year ended December 31, 2022
  - Net income: $29.0 million
  - Result: reported results
  source text: The net loss for the year ended December 31, 2022 was $29.0 million, which included non-cash gains of $1.3 million on warrants in 2022 as compared to $6.7 million in the prior year and approximately $2.3 million of stock-based compensation expense in 2022 as compared to $2.4 million in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923007580/0001437749-23-007580-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.